Goldman Sachs Downgrades Calumet to Neutral From Buy, Adjusts Price Target to $36 From $34
Calumet (CLMT) has an average rating of overweight and mean price target of $37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)